Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01712022 · ClinicalTrials.gov registry record
Evaluation of Corneal Epithelial Thickness Mapping
A clinical trial, sponsored by Optovue.
- Completed
- Registry status
- 88
- Enrollment target
NCT01712022: Completed study, sponsored by Optovue.
NCT01712022 is a clinical trial that has completed, run by Optovue. The registered enrollment target is 88 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01712022 has completed, sponsored by Optovue.
- COMPLETED
- Registry status
- 88 participants
- Enrollment target
Study Summary
Optovue has developed a new feature for mapping corneal epithelial thickness. The purpose of the study is to evaluate the accuracy and repeatability of the epithelial thickness measurement. Consented subjects will undergo a series of cornea measurements using optical coherence tomography (OCT) that will be used for analysis.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 88 participants |
| Start Date | 2012-10 |
| Est. Completion | 2013-11 |
What the finished NCT01712022 record still lists
NCT01712022 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 88 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT01712022 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01712022 about?
NCT01712022 is a clinical study titled "Evaluation of Corneal Epithelial Thickness Mapping". Optovue has developed a new feature for mapping corneal epithelial thickness. The purpose of the study is to evaluate the accuracy and repeatability of the epithelial thickness measurement. Consented subjects will undergo a series of cornea measurements using optical coherence tomography (OCT) that ...
What is the current status of trial NCT01712022?
This trial is currently completed. The enrollment target is 88 participants. The study started on 2012-10. Estimated completion is 2013-11.
Who is sponsoring clinical trial NCT01712022?
This trial is sponsored by Optovue, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03843463 · 88 participants · Phase 2
Escitalopram and Language Intervention for Subacute Aphasia
- NCT04066348 · 88 participants · Phase 2
TNF-α Treatment of Blast-Induced Tinnitus
- NCT04331704 · 88 participants · Phase 4
ANCHORS Alcohol & Sexual Health Study: UH3 Project
- NCT04536103 · 88 participants
Multi-Vendor Multi-Site Novel Accelerated MRI Relaxometry
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia